# Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer

> **NCT06507371** · PHASE3 · RECRUITING · sponsor: **Sir Run Run Shaw Hospital** · enrollment: 170 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **RADIATION:** node-sparing modified short-course radiotherapy
- **DRUG:** PD-1 antibody
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **RADIATION:** standard short-course radiotherapy

## Key facts

- **NCT ID:** NCT06507371
- **Lead sponsor:** Sir Run Run Shaw Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2026-02-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06507371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06507371, "Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06507371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*